Tokyo Tape
Sign in
← Oncolys BioPharma

Annual report

4588.TEDINET S100XTMG
Period2025-01-01 → 2025-12-31
Filed2026-03-25
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 78
MetricValuePeriodScopeSource row
Revenue¥29m2025-01-01 → 2025-12-31StandaloneNet sales
Revenue¥31m2024-01-01 → 2024-12-31StandaloneNet sales
Revenue¥63m2023-01-01 → 2023-12-31vStandaloneNet sales (5-year summary)
Revenue¥976m2022-01-01 → 2022-12-31vStandaloneNet sales (5-year summary)
Revenue¥642m2021-01-01 → 2021-12-31vStandaloneNet sales (5-year summary)
Operating income−¥2.0bn2025-01-01 → 2025-12-31StandaloneOperating income
Operating income−¥1.7bn2024-01-01 → 2024-12-31StandaloneOperating income
Ordinary income−¥2.1bn2025-01-01 → 2025-12-31StandaloneOrdinary income
Ordinary income−¥1.7bn2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income−¥1.9bn2023-01-01 → 2023-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.2bn2022-01-01 → 2022-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.5bn2021-01-01 → 2021-12-31vStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥2.1bn2025-01-01 → 2025-12-31StandaloneIncome before income taxes
Profit before tax−¥1.7bn2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Net income−¥2.1bn2025-01-01 → 2025-12-31StandaloneProfit loss
Net income−¥1.7bn2024-01-01 → 2024-12-31StandaloneProfit loss
Net income−¥1.9bn2023-01-01 → 2023-12-31vStandaloneNet income loss (5-year summary)
Net income−¥1.1bn2022-01-01 → 2022-12-31vStandaloneNet income loss (5-year summary)
Net income−¥1.6bn2021-01-01 → 2021-12-31vStandaloneNet income loss (5-year summary)
Total assets¥4.6bnat 2025-12-31StandaloneAssets
Total assets¥3.2bnat 2024-12-31StandaloneAssets
Total assets¥2.0bnat 2023-12-31vStandaloneTotal assets (5-year summary)
Total assets¥2.7bnat 2022-12-31vStandaloneTotal assets (5-year summary)
Total assets¥4.3bnat 2021-12-31vStandaloneTotal assets (5-year summary)
Total liabilities¥556mat 2025-12-31StandaloneLiabilities
Total liabilities¥447mat 2024-12-31StandaloneLiabilities
Net assets / equity¥4.0bnat 2025-12-31StandaloneNet assets
Net assets / equity¥2.8bnat 2024-12-31StandaloneNet assets
Net assets / equity¥1.5bnat 2023-12-31vStandaloneNet assets
Net assets / equity¥2.2bnat 2022-12-31vStandaloneNet assets (5-year summary)
Net assets / equity¥3.6bnat 2021-12-31vStandaloneNet assets (5-year summary)
Cash and deposits¥3.7bnat 2025-12-31StandaloneCash and deposits
Cash and deposits¥2.4bnat 2024-12-31StandaloneCash and deposits
Cash & equivalents¥3.4bnat 2025-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.2bnat 2024-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.3bnat 2023-12-31vStandaloneCash and cash equivalents
Cash & equivalents¥1.5bnat 2022-12-31vStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥3.2bnat 2021-12-31vStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.9bn2025-01-01 → 2025-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥2.0bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.3bn2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.7bn2022-01-01 → 2022-12-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.7bn2021-01-01 → 2021-12-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥8m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥5m2024-01-01 → 2024-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥5m2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥20m2022-01-01 → 2022-12-31vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥942,0002021-01-01 → 2021-12-31vStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥3.2bn2025-01-01 → 2025-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥2.9bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.1bn2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥114m2022-01-01 → 2022-12-31vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥3.1bn2021-01-01 → 2021-12-31vStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-802025-01-01 → 2025-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-77.172024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-108.922023-01-01 → 2023-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-66.312022-01-01 → 2022-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-95.52021-01-01 → 2021-12-31vStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥136.38at 2025-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥110.4at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥74.35at 2023-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥124.2at 2022-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥206.86at 2021-12-31vStandaloneNet assets per share (5-year summary)
Equity ratio87.6%at 2025-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio85.8%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio71.5%at 2023-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio81.2%at 2022-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio83.6%at 2021-12-31vStandaloneEquity to asset ratio (5-year summary)
Shares issued29,291,600at 2025-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued24,961,600at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued19,717,100at 2023-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued17,405,200at 2022-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued17,405,200at 2021-12-31vStandaloneTotal number of issued shares (5-year summary)
Employees38at 2025-12-31StandaloneNumber of employees
Employees35at 2024-12-31StandaloneNumber of employees
Employees34at 2023-12-31vStandaloneNumber of employees
Employees33at 2022-12-31vStandaloneNumber of employees
Employees33at 2021-12-31vStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 834
ItemContextValueUnit
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember1470377000JPY
Business consignment expenses sgaPrior1YearDuration_NonConsolidatedMember90665000JPY
Business consignment expenses sgaCurrentYearDuration_NonConsolidatedMember71697000JPY
Taxes and dues sgaPrior1YearDuration_NonConsolidatedMember40982000JPY
Taxes and dues sgaCurrentYearDuration_NonConsolidatedMember31862000JPY
License fee sgaPrior1YearDuration_NonConsolidatedMember32589000JPY
License fee sgaCurrentYearDuration_NonConsolidatedMember24148000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember1088997000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember1470377000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2026-03-25
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第22期(自　2025年１月１日　至　2025年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Company name in english cover pageFilingDateInstantOncolys BioPharma Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　浦田　泰生
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目１番28号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)03－5472－1578(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)執行役員　秦　耕平
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目１番28号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03－5472－1578(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)執行役員　秦　耕平
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE30058
Fund codeFilingDateInstant－
Security codeFilingDateInstant45880
Filer name in japaneseFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Filer name in englishFilingDateInstantOncolys BioPharma Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstantfalse
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantcte
Current fiscal year start dateFilingDateInstant2025-01-01
Current period end dateFilingDateInstant2025-12-31
Type of current periodFilingDateInstantFY
Current fiscal year end dateFilingDateInstant2025-12-31
Previous fiscal year start dateFilingDateInstant2024-01-01
Comparative period end dateFilingDateInstant2024-12-31
Previous fiscal year end dateFilingDateInstant2024-12-31
Next fiscal year start dateFilingDateInstant－
End date of quarterly or semi annual period of next fiscal yearFilingDateInstant－
Amendment flagFilingDateInstantfalse
Identification of document subject to amendmentFilingDateInstant－
Report amendment flagFilingDateInstantfalse
Xbrl amendment flagFilingDateInstantfalse

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2024-12-31pass
balance sheet identitynon_consolidated 2025-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net assetsnon_consolidated 2025-12-31pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · operating cash flownon_consolidated 2025-01-01/2025-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2025-12-31pass